Clinical Trials Logo

Pulmonary Aspergillosis clinical trials

View clinical trials related to Pulmonary Aspergillosis.

Filter by:

NCT ID: NCT03643185 Recruiting - ABPA Clinical Trials

Cytokine Profile of Allergic Bronchopulmonary Aspergillosis

Start date: December 2014
Phase:
Study type: Observational

The main aim of this study is to determine whether the levels of different inflammatory cytokines in the serum and BALF (bronchoalveolar lavage fluid) are relative to the severity and exacerbations of ABPA (allergic bronchopulmonary aspergillosis).

NCT ID: NCT03443336 Completed - Clinical trials for Pulmonary Aspergillosis

Azole-resistance in Aspergillus

Start date: June 1, 2017
Phase:
Study type: Observational

Prospective multi-center surveillance study on the prevalence of azole-resistant Aspergillus spp. in clinical isolates of patients with pulmonary colonization or invasive infections in Switzerland

NCT ID: NCT03391492 Completed - Clinical trials for Influenza With Pneumonia

Invasive Pulmonary Aspergillosis Complicating Influenza Infection

Start date: January 20, 2018
Phase:
Study type: Observational

Study the incidence and outcome of invasive pulmonary aspergillosis (IPA) in ICU patients with severe influenza and in influenza-negative control patients with severe community-acquired pneumonia

NCT ID: NCT03327727 Terminated - Clinical trials for Invasive Aspergillosis

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

Start date: February 20, 2018
Phase: Phase 2
Study type: Interventional

The purpose of the trial is to evaluate the safety and efficacy of a new antifungal with a novel mechanism of action in immunocompromised adults with invasive aspergillosis.

NCT ID: NCT03267394 Not yet recruiting - Clinical trials for Thymus and Activation Regulated Chemokine

Role of Thymus-And Activation-Regulated Chemokine (TARC) In Diagnosis Of Allergic Bronchopulmonary Aspergillosis

Start date: October 2017
Phase: N/A
Study type: Observational

This study aims to assess the value of TARC in diagnosis of allergic Bronchopulmonary Aspergillosis.

NCT ID: NCT03265366 Completed - Clinical trials for Allergic Bronchopulmonary Aspergilloses

Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses

ABPA-MR
Start date: September 14, 2017
Phase: N/A
Study type: Interventional

The aim of the study is to compare the concordance between chest computerized tomography-scan (CTscan) and Magnetic resonance Imaging (MRI) for the description of the abnormalities seen in Allergic BronchoPulmonary Aspergillosis (ABPA).

NCT ID: NCT03133299 Completed - Clinical trials for Allergic Bronchopulmonary Aspergilloses

A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma

Start date: December 1, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Allergic bronchopulmonary aspergillosis (ABPA) is a immunological pulmonary disorder caused by hypersensitive reaction to spores of Aspergillus fumigatus. The prevalence of disease is about 1-2% in asthmatics and 2-15% in patients with cystic fibrosis. The interest in ABPA stems from the fact that the disease is glucocorticoid-sensitive and early treatment can prevent progression to end-stage lung disease. Recently anti-Th2 therapies have been suggested as treatment for ABPA. Vitamin D has been shown to suppress the Th2 responses and decrease the levels of Th2 interleukins. Hence, the investigators propose to assess the role of vitamin D in treating ABPA.

NCT ID: NCT03059992 Completed - Clinical trials for Invasive Candidiasis

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

FURI
Start date: April 1, 2017
Phase: Phase 3
Study type: Interventional

This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.

NCT ID: NCT03027089 Recruiting - Clinical trials for Chronic Pulmonary Aspergillosis

Aspergillus-specific IgG Assays for the Diagnosis of Chronic Pulmonary Aspergillosis (CPA)-Multicenter Study

Start date: January 2017
Phase: N/A
Study type: Observational

Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA)

NCT ID: NCT02955966 Completed - Clinical trials for Aspergillosis and Haematological Malignancy

PET/CT Guided Antifungal Stewardship in Invasive Pulmonary Aspergillosis

OPTIFIL
Start date: June 2, 2017
Phase: N/A
Study type: Interventional

OPTIFIL is a pilot prospective multicenter study based over the hypothesis that the normalization of the functional imaging 18F-FDG-PET/CT during the Invasive pulmonary aspergillosis (IPA) could occur earlier than that of conventional imaging. This study evaluates the therapeutic response through a systematic 18F-FDG-PET/CT at week 6. The latter response will be correlated with the kinetics of selected biomarkers including antigens (galactomannan, β-D glucans), circulating Aspergillus DNA and anti-Aspergillus host response markers in addition to the conventional imaging tools obtained at weeks 6 and 12.